A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
25
03
2019
revised:
01
05
2019
accepted:
28
05
2019
pubmed:
20
6
2019
medline:
17
6
2020
entrez:
20
6
2019
Statut:
ppublish
Résumé
Cancer scientists and clinicians are mourning the death of one of the most accomplished members of their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy and was instrumental for the discovery and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening the concept of targeted EGFR therapy to encompass other receptor tyrosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy. Dr. Mendelsohn, who died on January 7, 2019, always led by the strength of his accomplishments and the humility of his character. Above all, he was a well-revered mentor and clinician, who extended compassion and the gift of his time to patients, colleagues, and mentees alike. In tribute to Dr. Mendelsohn,
Identifiants
pubmed: 31213466
pii: 0008-5472.CAN-19-0989
doi: 10.1158/0008-5472.CAN-19-0989
doi:
Substances chimiques
Antibodies, Monoclonal
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Biography
Historical Article
Journal Article
Portrait
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4315-4323Sujets (noms de personnes)
{'last_name': 'Mendelsohn', 'fore_name': 'John', 'initials': 'J'}
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.